MAPT and Alzheimer disease: By potentially reducing brain exposure to chronic hyperinsulinemia that occurs even in non-diabetic states of insulin resistance [9], empagliflozin could inhibit the aggregation of pathogenic proteins such as amyloid-beta (Aβ) and Tau that underlie the pathogenesis of Alzheimer’s disease (AD) [10,11,12,13].